

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.\*

*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)  
(Stock Code: 01099)*

## ANNOUNCEMENT

### PROPOSED CHANGE OF EXECUTIVE DIRECTOR

#### RESIGNATION OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Sinopharm Group Co. Ltd. (the “**Company**”) hereby announces that on 6 November 2025, due to the work arrangement, Mr. Sun Jinglin (“**Mr. Sun**”) tendered his resignation to the Board as an executive Director and a member of the strategy and investment committee of the Board (the “**Strategy and Investment Committee**”). The above resignation shall take immediate effect.

Mr. Sun confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders (the “**Shareholders**”) and creditors of the Company.

During the term of office, Mr. Sun diligently and faithfully performed his duties. The Board would like to take this opportunity to express its sincere gratitude to his contribution to the sustainable and stable development and the continuous improvement of the corporate governance level of the Company.

*\* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

## **PROPOSED APPOINTMENT OF EXECUTIVE DIRECTOR**

On the same day, the Board resolved to propose to appoint Mr. Yang Binghua (“**Mr. Yang**”) as an executive Director (the “**Proposed Appointment of Director**”).

The Proposed Appointment of Director was proposed by the nomination committee of the Board (the “**Nomination Committee**”) according to the nomination procedures for Directors of the Company and based on the needs of the Company and has submitted to the Board for review after considering the Director candidate’s relevant qualification by the Nomination Committee, and will then be submitted by the Board to the general meeting for final approval.

In accordance with the articles of association of the Company (the “**Articles of Association**”), the Proposed Appointment of Director is subject to the approval by the Shareholders at the general meeting of the Company.

Upon the approval of the Proposed Appointment of Director by the Shareholders, the Company will enter into a service contract with Mr. Yang, and Mr. Yang’s term of office as a Director shall commence from the date of his appointment by the general meeting and end on the expiration of the term of the current session of the Board. Pursuant to the Articles of Association, Mr. Yang will be subject to retirement by rotation and re-election upon the expiry of his term of office. The remuneration of Mr. Yang will be determined by the Board according to the authorization granted at the general meeting of the Company and in accordance with the Company’s remuneration standard regarding Directors implemented from time to time. According to the Company’s current remuneration standard, executive Directors will receive remuneration based on the performance appraisal, incentive measures and annual salary standard settlement.

## **BIOGRAPHY OF MR. YANG**

**Mr. Yang Binghua**, aged 45, is a deputy secretary of the Party Committee of the Company. Mr. Yang obtained a master’s degree in Public Administration from School of Government of Peking University in 2011. Mr. Yang previously served as the deputy department head of the second secretarial department of the State Council State-owned Assets Supervision and Administration Commission (“**SASAC**”), a deputy director of the Party Committee for offices directly under SASAC, the deputy department head and the department head of the communication department of the Party Committee for offices directly under SASAC, the deputy secretary of the Party Committee of Shanghai Shyndec Pharmaceutical Co., Ltd. (上海現代製藥股份有限公司), and the director of the work department of the Party Committee (the organization department of the Party Committee and the communication department of the Party Committee) of China National Pharmaceutical Group Co., Ltd. (中國醫藥集團有限公司). In the past

three years, Mr. Yang served as a non-executive director of China Traditional Chinese Medicine Holdings Co. Limited (中國中藥控股有限公司) (a company listed on the Hong Kong Stock Exchange, stock code: 0570) and a director of Chongqing Taiji Industry (Group) Co., Ltd. (重慶太極實業(集團)股份有限公司) (a company listed on the Shanghai Stock Exchange, stock code: 600129). Mr. Yang has served as a deputy secretary of the Party Committee of the Company since October 2025.

Save as disclosed above, as at the date of this announcement, Mr. Yang did not have any relationship with any Director, senior management or substantial or controlling Shareholder of the Company, or have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, Mr. Yang did not hold any other positions in the Company or any of its subsidiaries, or any directorship in other listed companies in the last three years.

Save as disclosed above, the Company is not aware of any other matter that needs to be brought to the attention of the Shareholders or any matter in relation to the Proposed Appointment of Director that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

A circular containing, among other things, details of the Proposed Appointment of Director will be despatched to the Shareholders of the Company in due course according to the manner in which the Shareholders have elected to receive corporate communications.

By order of the Board  
**Sinopharm Group Co. Ltd.**  
*Zhao Bingxiang*  
**Chairman**

Shanghai, the PRC  
6 November 2025

*As at the date of this announcement, the executive Director is Mr. Lian Wanyong; the non-executive Directors are Mr. Zhao Bingxiang, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Feng Rongli; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.*